Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.
In a recent study published in the journal eGastroenterology, researchers delved into the latest therapeutic strategies for managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The paper discusses emerging treatments ranging from immune-modulating drugs and biologics to novel approaches like microRNA upregulators and stem cell therapies, highlighting the need for precision medicine in IBD care.
Cardiopulmonary fitness, body composition, and persistent long COVID symptoms of individuals who had SARS-CoV-2 infections.
The research review indicates that people with HIV, especially those with low CD4 cell counts, face greater risks of severe COVID-19 outcomes and have suboptimal immune responses to SARS-CoV-2. Antiretroviral therapy aids in clearing infections, and a third vaccine dose reduces the risk of breakthrough infections among this population.
Researchers assessed immune resilience (IR) metrics in individuals across diverse infectious and non-infectious models.
The study reveals that MIS-C patients, post SARS-CoV-2 infection, develop a unique immune response against the virus' N protein, indicating a cross-reactivity with the self-protein SNX8, which might link the infection to the ensuing inflammatory syndrome.
Individuals who are immunocompromised are considered at higher risk for severe or longer disease with COVID-19. Understanding the systemic immune response is vital for research efforts to reduce its effects on multiple organs.
Researchers explored the pathophysiological variables and coagulation abnormalities associated with long coronavirus disease (COVID).
Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.
A new study led by Washington University School of Medicine in St. Louis reveals at least one cause of low white blood cell counts in patients treated for glioblastoma and demonstrates a potential treatment strategy that improves survival in mice.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.
In a new study, researchers observed that coronavirus disease 2019 (COVID-19) progression and inflammatory responses are associated with changes in the metabolome and microbiome.
Over the past two decades, numerous complex cancer therapies called antibody drug conjugates (ADCs) have been tested in clinical trials and approved for use in patients.
Researchers summarize current knowledge about underlying mechanisms and potential therapeutic approaches for the effects of COVID-19 on the gut.
Researchers from Italy investigated the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in infants younger than three months and compared the reported coronavirus disease 2019 (COVID-19) severity scores for the pediatric population.
In a new study, researchers described a case of a patient with acute respiratory failure and ischemic stroke.
Recently, authors highlighted the potential role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in triggering the relapse of mycosis fungoides, a type of cutaneous T-cell lymphoma.
High levels of TNFR might successfully predict the increased severity of COVID-19.
In new research, researchers estimated the D-dimer levels and characterized lymphocyte subsets and cytokine profiles in severe coronavirus disease 2019 (COVID-19) patients.
A new study determines the antiviral efficacy of favipiravir against ZIKV and SARS-CoV-2 infections.